Description
The RUU-PL7F12 monoclonal antibody specifically recognizes CD61, a 110 kDa type I transmembrane glycoprotein, also known as Glycoprotein IIIa (gpIIIa), the common β-subunit (integrin β3-chain) of the gpIIb/IIIa complex and the vitronectin receptor (VNR). The gpIIb/IIIa complex and the VNR are integrins, ie, α/β-heterodimeric glycoprotein complexes that are involved in cell adhesion. With the CD41 antigen (gpIIb or αIIb), the CD61 antigen forms the gpIIb/IIIa complex, which acts as a receptor for fibrinogen, von Willebrand factor (vWf), fibronectin, and vitronectin on activated platelets. With the CD51 antigen (VNR α-chain or αv), the CD61 antigen forms the VNR, which mediates activation-independent cell adhesion to vitronectin, vWf, fibrinogen, and thrombospondin. The CD61 antigen is found on all normal resting and activated platelets. Platelets from individuals with Glanzmann's thrombasthenia show a >90% reduction of binding of CD61, and heterozygote carriers of the disorder show approximately 50% reduction. The CD61 antigen is also found on endothelial cells, megakaryocytes, and on some myeloid, erythroid, and T-lymphoid leukemic cell lines.
For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime two or more BD Horizon Brilliant dyes (including BD OptiBuild Brilliant reagents) are used in the same experiment. Fluorescent dye interactions may cause staining artifacts which may affect data interpretation. The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794).
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated with BD Horizon BUV661 under optimal conditions that minimize unconjugated dye and antibody.
1. This antibody was developed for use in flow cytometry.
2. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
3. Researchers should determine the optimal concentration of this reagent for their individual applications.
4. An isotype control should be used at the same concentration as the antibody of interest.
5. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
6. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
7. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
8. BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
9. BD Horizon Brilliant Ultraviolet 661 is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,227,187; 8,575,303; 8,354,239.
